Cargando…
VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study
OBJECTIVE: Evaluate safety and effectiveness of VYC-12 (Juvéderm Volite; an injectable crosslinked hyaluronic acid gel designed to improve skin quality attributes such as surface smoothness and hydration) for facial intradermal injection. MATERIALS AND METHODS: In a prospective, single-arm study, su...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817835/ https://www.ncbi.nlm.nih.gov/pubmed/31749628 http://dx.doi.org/10.2147/CCID.S216222 |
_version_ | 1783463504405069824 |
---|---|
author | Niforos, François Ogilvie, Patricia Cavallini, Maurizio Leys, Christophe Chantrey, Jonquille Safa, Marva Abrams, Steve Hopfinger, René Marx, Ann |
author_facet | Niforos, François Ogilvie, Patricia Cavallini, Maurizio Leys, Christophe Chantrey, Jonquille Safa, Marva Abrams, Steve Hopfinger, René Marx, Ann |
author_sort | Niforos, François |
collection | PubMed |
description | OBJECTIVE: Evaluate safety and effectiveness of VYC-12 (Juvéderm Volite; an injectable crosslinked hyaluronic acid gel designed to improve skin quality attributes such as surface smoothness and hydration) for facial intradermal injection. MATERIALS AND METHODS: In a prospective, single-arm study, subjects with moderate/severe cheek skin roughness per Allergan Skin Roughness Scale (ASRS) received VYC-12 in the cheeks and forehead, and/or neck, with touch-up treatment to correct asymmetry 30 days later and optional repeat treatment 9 months after last treatment. The primary effectiveness measure was ASRS responder rate (percentage of cheeks with ≥1-point improvement from baseline) at month 1. Skin hydration was instrument-assessed. RESULTS: Of 131 subjects treated, 31 (23.7%) received touch-up treatment. ASRS responder rate was 96.2% at month 1, 76.3% at month 4, 34.9% at month 6, and 87.1% after repeat treatment. Responder rate in cheeks with severe baseline roughness was 93.8%, 83.1%, and 52.3% at months 1, 4, and 6, respectively. Skin hydration improved significantly (P<0.01) from baseline at all timepoints through month 9. Injection site responses were as expected. All treatment-related adverse events were mild/moderate. CONCLUSION: VYC-12 safely and effectively improved skin smoothness up to 6 months and hydration lasting 9 months. |
format | Online Article Text |
id | pubmed-6817835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68178352019-11-20 VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study Niforos, François Ogilvie, Patricia Cavallini, Maurizio Leys, Christophe Chantrey, Jonquille Safa, Marva Abrams, Steve Hopfinger, René Marx, Ann Clin Cosmet Investig Dermatol Clinical Trial Report OBJECTIVE: Evaluate safety and effectiveness of VYC-12 (Juvéderm Volite; an injectable crosslinked hyaluronic acid gel designed to improve skin quality attributes such as surface smoothness and hydration) for facial intradermal injection. MATERIALS AND METHODS: In a prospective, single-arm study, subjects with moderate/severe cheek skin roughness per Allergan Skin Roughness Scale (ASRS) received VYC-12 in the cheeks and forehead, and/or neck, with touch-up treatment to correct asymmetry 30 days later and optional repeat treatment 9 months after last treatment. The primary effectiveness measure was ASRS responder rate (percentage of cheeks with ≥1-point improvement from baseline) at month 1. Skin hydration was instrument-assessed. RESULTS: Of 131 subjects treated, 31 (23.7%) received touch-up treatment. ASRS responder rate was 96.2% at month 1, 76.3% at month 4, 34.9% at month 6, and 87.1% after repeat treatment. Responder rate in cheeks with severe baseline roughness was 93.8%, 83.1%, and 52.3% at months 1, 4, and 6, respectively. Skin hydration improved significantly (P<0.01) from baseline at all timepoints through month 9. Injection site responses were as expected. All treatment-related adverse events were mild/moderate. CONCLUSION: VYC-12 safely and effectively improved skin smoothness up to 6 months and hydration lasting 9 months. Dove 2019-10-24 /pmc/articles/PMC6817835/ /pubmed/31749628 http://dx.doi.org/10.2147/CCID.S216222 Text en © 2019 Niforos et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Niforos, François Ogilvie, Patricia Cavallini, Maurizio Leys, Christophe Chantrey, Jonquille Safa, Marva Abrams, Steve Hopfinger, René Marx, Ann VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study |
title | VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study |
title_full | VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study |
title_fullStr | VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study |
title_full_unstemmed | VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study |
title_short | VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study |
title_sort | vyc-12 injectable gel is safe and effective for improvement of facial skin topography: a prospective study |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817835/ https://www.ncbi.nlm.nih.gov/pubmed/31749628 http://dx.doi.org/10.2147/CCID.S216222 |
work_keys_str_mv | AT niforosfrancois vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT ogilviepatricia vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT cavallinimaurizio vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT leyschristophe vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT chantreyjonquille vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT safamarva vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT abramssteve vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT hopfingerrene vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy AT marxann vyc12injectablegelissafeandeffectiveforimprovementoffacialskintopographyaprospectivestudy |